{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:57:44Z","timestamp":1760317064860,"version":"build-2065373602"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2003,4,17]],"date-time":"2003-04-17T00:00:00Z","timestamp":1050537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The current dose\u2010optimizing Phase II study evaluated the effect of weekly paclitaxel and gemcitabine on the response rate and survival of patients with non\u2010small cell lung carcinoma (NSCLC) using dose modifications that permitted optimal treatment intensity.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Forty\u2010five patients (40 with TNM Stage IV and 5 with TNM Stage IIIB NSCLC) were treated with gemcitabine at 1000 mg\/m<jats:sup>2<\/jats:sup> via a 30\u2010minute intravenous (i.v.) infusion and with paclitaxel at 100 mg\/m<jats:sup>2<\/jats:sup> via a 60\u2010minute i.v. infusion. The first 3 patients received chemotherapy on Days 1, 8, and 15 every 4 weeks; the next 42 patients, participating in the Phase II trial, received chemotherapy on Days 1 and 8 every 3 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The 3 patients who received paclitaxel and gemcitabine on Days 1, 8, and 15 every 4 weeks tolerated the treatment poorly. One patient died suddenly after Day 15 treatment during the first cycle, and the other 2 patients discontinued the treatment because of unacceptable toxicity before the third cycle of chemotherapy. The next 42 patients, 40 of whom were evaluable, entered this trial between May 2000 and April 2001. They received paclitaxel at 100 mg\/m<jats:sup>2<\/jats:sup> i.v. followed by gemcitabine at 1000 mg\/m<jats:sup>2<\/jats:sup> i.v. on Days 1 and 8 every 3 weeks. Two patients (5%) achieved complete response, 20 (50%) achieved partial response, and 8 (20%) had stable disease. Median survival (MS) was 9.8 months; and 1\u2010year survival was 35%. The 32 patients with performance status (PS) 0 or 1 had an MS of 11 months; the 8 patients with PS 2 had an MS of 3 months. Toxicity (especially hematologic toxicity, neuropathy, and alopecia) was minimal.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>A weekly paclitaxel and gemcitabine regimen that incorporated the authors' dose modifications resulted in good efficacy with minimal toxicity. Cancer 2003;97:2242\u20137. \u00a9 2003 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.11319<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11319","type":"journal-article","created":{"date-parts":[[2003,4,21]],"date-time":"2003-04-21T06:33:26Z","timestamp":1050906806000},"page":"2242-2247","source":"Crossref","is-referenced-by-count":12,"title":["Weekly paclitaxel and gemcitabine chemotherapy for metastatic non\u2010small cell lung carcinoma (NSCLC)"],"prefix":"10.1002","volume":"97","author":[{"given":"Vera","family":"Hirsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Whittom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Ofiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Pintos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Langleben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,4,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920901)70:5<1102::AID-CNCR2820700514>3.0.CO;2-5"},{"key":"e_1_2_6_3_2","first-page":"19","article-title":"Polychemotherapy in advanced non\u2010small cell lung cancer: a meta\u2010analysis","volume":"34","author":"Soquet PJ","year":"1993","journal-title":"Lancet."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7010.899"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.4.633"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.8.1301"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1307"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1535"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00444-0"},{"issue":"6","key":"e_1_2_6_10_2","first-page":"32","article-title":"Schedule\u2010 and dose\u2010intensified paclitaxel as weekly 1\u2010hour infusion in pretreated solid tumors: results of a phase I\/II trial","volume":"23","author":"Loffler TM","year":"1996","journal-title":"Semin Oncol."},{"issue":"6","key":"e_1_2_6_11_2","first-page":"55","article-title":"Phase I\/II trial of weekly paclitaxel in patients with advanced lung cancer","volume":"23","author":"Akerley W","year":"1996","journal-title":"Semin Oncol."},{"key":"e_1_2_6_12_2","first-page":"468a","article-title":"Second\u2010line treatment with paclitaxel and gemcitabine in patients with non\u2010small cell lung cancer who failed cisplatin\u2010based chemotherapy","volume":"17","author":"Georgoulias V","year":"1998","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_13_2","first-page":"516a","article-title":"Results of a phase II study with taxol and Gemzar in metastatic non\u2010small cell lung cancer","volume":"19","author":"Monnier A","year":"2000","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_14_2","first-page":"522a","article-title":"Phase II study of gemcitabine and paclitaxel in metastatic non\u2010small cell lung cancer","volume":"19","author":"Auerbach M","year":"2000","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_15_2","first-page":"488a","article-title":"A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non\u2010small cell lung cancer: a preliminary analysis","volume":"19","author":"Kosmidis PA","year":"2000","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_16_2","first-page":"308a","article-title":"A EORTC randomized phase III trial of three chemotherapy regimens in advanced non\u2010small cell lung cancer","volume":"20","author":"VanMeerbeeck JP","year":"2001","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04644-4"},{"key":"e_1_2_6_18_2","first-page":"292a","article-title":"Gemvin III: A phase III study of gemcitabine plus vinorelbine (GV) compared to cisplatin plus vinorelbine or gemcitabine chemotherapy (PCT) for stage IIIB or IV non\u2010small cell lung cancer (NSCLC): An Italo\u2010Canadian study","volume":"21","author":"Gridelli C","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010815)92:4<830::AID-CNCR1389>3.0.CO;2-C"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.405"},{"key":"e_1_2_6_21_2","first-page":"320A","article-title":"A multicenter randomized trial of docetaxel plus gemcitabine versus weekly paclitaxel plus gemcitabine in patients with non\u2010small cell lung cancer: ACORN 9901 study trial","volume":"21","author":"Patel R","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_22_2","first-page":"214","article-title":"Phase II multicenter trial with weekly paclitaxel and gemcitabine in patients with advanced (Stage IIIB & IV) non\u2010small cell lung cancer (NSCLC): final report","volume":"2673","author":"Hirsh V","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_23_2","first-page":"314a","article-title":"Prospective randomized study of four third generation chemotherapy regimens in patients (pts) with advanced non\u2010small cell lung cancer: a Minnie Pearl Cancer Research Network Trial","volume":"1253","author":"Thompson D","year":"2001","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_24_2","first-page":"308a","article-title":"Cisplatin\/gemcitabine (CG) vs cisplatin\/gemcitabine\/vinorelbine (CGV) vs sequential doublets of gemcitabine\/vinorelbine followed by lfosfamide\/vinorelbine (GV\/IV) in advanced non\u2010small cell lung cancer (NSCLC): results of a Spanish Lung Cancer Group phase III trial (GEPC\/98\u201002)","volume":"1229","author":"Alberola V","year":"2001","journal-title":"Proc Am Soc Clin Oncol."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11319","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:13:22Z","timestamp":1760303602000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11319"}},"subtitle":["<i>A dose\u2010optimizing phase II trial<\/i>"],"short-title":[],"issued":{"date-parts":[[2003,4,17]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1002\/cncr.11319"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11319","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2003,4,17]]}}}